Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

/PRNewswire/ — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a late-stage pharmaceutical company with a broad portfolio of drug…Read More